Current treatment recommendations and considerations for cryopyrin-associated periodic syndrome.

doi:10.1586/1744666X.2015.1077702

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Current treatment recommendations and considerations for cryopyrin-associated periodic syndrome.

Expert review of clinical immunology - 1 Jan 2015

Koné-Paut Isabelle, Galeotti Caroline

Abstract excerpt

Cryopyrin-associated periodic syndrome (CAPS) encompasses a spectrum of three phenotypes of increasing severity. The syndrome is due to dominant mutations in NLRP3, which encodes a key component of the innate immunity that regulates the secretion of IL-1β. CAPS manifests as systemic inflammation, which compromises quality of life and leads to serious complications and handicap. Anti-IL-1 drugs have shown...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal
Share to Antibodies, Monoclonal, Humanized
Share to Cryopyrin-Associated Periodic Syndromes
Share to Immunity, Innate

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Interleukin 1 Receptor Antagonist Protein

Share to Interleukin-1beta

Share to NLR Family, Pyrin Domain-Containing 3 Protein

Share to Receptors, Interleukin-1

Source

Open in PubMed

Identifiers

PMID: 26312542
DOI: 10.1586/1744666X.2015.1077702

Genes

CAPS
NLRP3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.